Adage Capital Partners
CCCC icon

Adage Capital Partners’s C4 Therapeutics CCCC Stock Holding History

Adage Capital Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,000
Closed -$286K – 899
2025
Q2 		$286K Sell
200,000
-1,350,000
-87% -$1.96M ﹤0.01% 822
2025
Q1 		$2.48M Hold
1,550,000
– – ﹤0.01% 752
2024
Q4 		$5.58M Buy
1,550,000
+1,030,000
+198% +$5.12M 0.01% 706
2024
Q3 		$2.96M Buy
+520,000
New +$3.13M 0.01% 758
2022
Q1 		– Sell
-996,477
Closed -$32.1M – 1087
2021
Q4 		$32.1M Buy
996,477
+185,000
+23% +$7.32M 0.06% 331
2021
Q3 		$36.3M Buy
811,477
+121,477
+18% +$5.2M 0.07% 278
2021
Q2 		$26.1M Sell
690,000
-190,498
-22% -$6.82M 0.05% 374
2021
Q1 		$32.6M Sell
880,498
-10,000
-1% -$398K 0.07% 313
2020
Q4 		$29.5M Buy
+890,498
New +$25.8M 0.06% 318

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners's CCCC Position: Q3 2025 in Review

Adage Capital Partners sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 200,000 shares — an estimated $286K sold.

Adage Capital Partners first reported a position in CCCC in Q4 2020 and held it in 9 quarters. The position peaked at $36.3M in Q3 2021. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • Adage Capital Partners reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 200,000 C4 Therapeutics shares in Q3 2025, an estimated $286K.
  • Adage Capital Partners first reported a position in C4 Therapeutics in Q4 2020 and held it in 9 quarters.
  • Adage Capital Partners's C4 Therapeutics position peaked at $36.3M in Q3 2021.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.